{"entity":{"id":"paper-nct05186974-j-thorac-oncol-2026","kind":"paper","name":"First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study","aka":[],"tldr":"Published report from the EVOKE-02 trial registered as NCT05186974, in Journal of Thoracic Oncology (2026), chosen as the most cited paper whose own text cites the registry id.","summary":"Introduction: Sacituzumab govitecan (SG) is a Trop-2-directed antibody-drug conjugate previously studied in patients with pretreated metastatic NSCLC (mNSCLC). Here, we report the results of EVOKE-02 (NCT05186974), a global, open-label, multicohort phase 2 study of SG plus pembrolizumab as first-line treatment in patients with mNSCLC.\n\nMethods: Adult patients without prior systemic mNSCLC treatment, and no actionable genomic alterations, received SG 10 mg/kg intravenously on days 1 and 8 plus pembrolizumab 200 mg intravenously on day 1 of 21-day cycles. The primary end point was objective response rate (ORR) per independent review committee, and secondary end points included progression-free survival (PFS) and safety.\n\nResults: at data cutoff (June 3, 2024), there were 30 patients with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) more than or equal to 50% (cohort A) and 62 patients with PD-L1 TPS less than 50% (cohort B). ORR (95% confidence interval) was 66.7% (47.2-82.7) for cohort A and 29.0% (18.2-41.9) for cohort B. Median (95% confidence interval) PFS was 13.1 (6.7-not reached) months for cohort A and 7.0 (4.2-12.9) months for cohort B. Trop-2 expression did not correlate with greater clinical efficacy (PFS, ORR) from treatment with SG plus pembrolizumab. Grade 3 or greater treatment-emergent adverse events (TEAEs) occurred in 70 patients (76.1%); the most common TEAE was neutropenia (17.4%). TEAEs leading to discontinuation of any study drug occurred in 25 patients (27.2%).\n\nConclusions: SG plus pembrolizumab demonstrated activity as treatment for mNSCLC, especially in patients with PD-L1 TPS more than or equal to 50%. AEs were manageable and consistent with the known safety profile of each individual agent.\n\nIndexed on Europe PMC as PubMed record 41173143 (DOI 10.1016/j.jtho.2025.10.016). Its abstract cites the registry id NCT05186974, which is how it was matched to this trial; no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"J Thorac Oncol 2026","url":"https://doi.org/10.1016/j.jtho.2025.10.016"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/41173143/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/41173143"},{"label":"ClinicalTrials.gov NCT05186974","url":"https://clinicaltrials.gov/study/NCT05186974"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05186974"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-thoracic-oncology"],"dependsOn":[],"notes":[],"journal":"Journal of Thoracic Oncology","year":2026,"doi":"10.1016/j.jtho.2025.10.016","pmid":"41173143","authors":"Reck M, Patel JD, Gray JE, et al.","paperType":"observational","findings":[],"whatItMeans":"This is the paper Europe PMC returns for registry id NCT05186974 with the most citations, so it is the natural first reading for anyone following the EVOKE-02 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.","caveats":["Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-nct05186974-j-thorac-oncol-2026/","neighbours":{"trial":[{"id":"nct05186974","kind":"trial","name":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","route":"/trials/nct05186974/"}],"journal":[{"id":"journal-of-thoracic-oncology","kind":"journal","name":"Journal of Thoracic Oncology","route":"/journals/journal-of-thoracic-oncology/"}]}}